Nanoviricides (NNVC) Other financing activities (2013 - 2021)
Nanoviricides (NNVC) posted Other financing activities of $37408.0 for Q4 2021, up 191.19% sequentially from -$41024.0 in Q4 2020, and up 191.19% YoY from $12846.8 in Q4 2020.
Nanoviricides (NNVC) Other financing activities (2013 - 2021) Analysis & Trends
Nanoviricides has reported Other financing activities for 6 years, with the latest figure at $37408.0 in Q4 2021.
- Quarterly Other financing activities rose 191.19% year-over-year to $37408.0 in Q4 2021, while the trailing twelve-month figure through Mar 2022 was $37408.0 (down 73.48% YoY) and the FY2020 annual result came in at $12190.0, changed N/A from the prior year.
- Other financing activities climbed to $37408.0 in Q4 2021 per NNVC's latest filing, from -$41024.0 in the prior quarter.
- Over five years, Other financing activities peaked at $242105.0 in Q3 2019 and troughed at -$41024.0 in Q4 2020.
- A 3-year average of $84116.6 and a median of $41024.0 in 2020 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2020 and 2021: Other financing activities plunged 129.08% in 2020, then soared 191.19% in 2021.
- Over 3 years, Other financing activities stood at $141070.0 in 2019, then slumped by 129.08% to -$41024.0 in 2020, then jumped by 191.19% to $37408.0 in 2021.
- According to Business Quant data, Other financing activities over the past three periods registered $37408.0, -$41024.0, and $41024.0 for Q4 2021, Q4 2020, and Q3 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - |
| 10 | Nanoviricides | 29.42 Mn | 26.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 37,408.00 |
| Dec 31, 2021 | 37,408.00 |
| Dec 31, 2020 | -41,024.00 |
| Dec 31, 2020 | -41,024.00 |
| Sep 30, 2020 | 41,024.00 |
| Sep 30, 2020 | 41,024.00 |
| Dec 31, 2019 | 141,070.00 |
| Dec 31, 2019 | 141,070.00 |
| Sep 30, 2019 | 242,105.00 |
| Sep 30, 2019 | 242,105.00 |
| Mar 31, 2015 | 2.00 |
| Mar 31, 2015 | 2.00 |
| Dec 31, 2014 | 60,998.00 |
| Dec 31, 2014 | 60,998.00 |
| Sep 30, 2014 | 6.68 Mn |
| Sep 30, 2014 | 6.68 Mn |
| Jun 30, 2014 | -2.00 |
| Jun 30, 2014 | -2.00 |
| Mar 31, 2014 | 525,000.00 |
| Mar 31, 2014 | 525,000.00 |